Literature DB >> 23579608

Recurrence of retinopathy of prematurity following bevacizumab monotherapy: is it only the tip of the iceberg?

Kamiar Mireskandari, Gillian G W Adams, Nasrin N Tehrani.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23579608     DOI： 10.1001/jamaophthalmol.2013.711

Source DB:  PubMed          Journal:  JAMA Ophthalmol        ISSN： 2168-6165            Impact factor:   7.389


× No keyword cloud information.
  3 in total

Review 1.  Pharmacologic interventions for the prevention and treatment of retinopathy of prematurity.

Authors:  Kay D Beharry; Gloria B Valencia; Douglas R Lazzaro; Jacob V Aranda
Journal:  Semin Perinatol       Date:  2016-01-29       Impact factor: 3.300

2.  Evaluation of Potential Systemic Adverse Events Related to Fluorescein Angiography in Pediatric Patients.

Authors:  Ru-Ik Chee; Mrinali P Gupta; Nita G Valikodath; Emily Cole; Anton Orlin; Tala Al-Khaled; Irene Rusu; Samir N Patel; June Han; Vivien Yap; Karyn E Jonas; Peter J Campbell; Michael F Chiang; R V Paul Chan
Journal:  Ophthalmol Retina       Date:  2019-12-16

3.  COMPARISON OF INTRAVITREAL INJECTION OF RANIBIZUMAB VERSUS LASER THERAPY FOR ZONE II TREATMENT-REQUIRING RETINOPATHY OF PREMATURITY.

Authors:  Guoming Zhang; Mingmin Yang; Jian Zeng; Georgios Vakros; Kangjin Su; Miaohong Chen; Huilin Li; Ruyin Tian; Na Li; Song Tang; Honghui He; Wenjing Tan; Xiangmei Song; Runsen Zhuang
Journal:  Retina       Date:  2017-04       Impact factor: 4.256
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.